Loading...

Discounted Cash Flow (DCF) Analysis Unlevered


Therapix Biosciences Ltd.

Therapix Biosciences Ltd. (TRPX)

0.317 €
-0.313 (-49.68%)

Operating Data

Year
A/P
2017
Projected
2018
Projected
2019
Projected
2020
Projected
2021
Projected
2022
Projected
2023
Projected
Revenue -------
Revenue (%)
EBITDA -------
EBITDA (%)
EBIT -------
EBIT (%)
Depreciation -------
Depreciation (%)

Balance Sheet Data

Year
A/P
2017
Projected
2018
Projected
2019
Projected
2020
Projected
2021
Projected
2022
Projected
2023
Projected
Total Cash -------
Total Cash (%)
Account Receivables -------
Account Receivables (%)
Inventories -------
Inventories (%)
Accounts Payable -------
Accounts Payable (%)
Capital Expenditure -------
Capital Expenditure (%)

Weighted Average Cost Of Capital

Share price $ 0.317
Diluted Shares Outstanding -
Cost of Debt
Tax Rate -
After-tax Cost of Debt -%
Risk-Free Rate
Market Risk Premium
Cost of Equity 3.93
Total Debt -
Total Equity -
Total Capital -
Debt Weighting -
Equity Weighting -
Wacc

Build Up Free Cash

Year
A/P
2017
Projected
2018
Projected
2019
Projected
2020
Projected
2021
Projected
2022
Projected
2023
Projected
Revenue -------
EBITDA -------
EBIT -------
Tax Rate -------
EBIAT -------
Depreciation -------
Accounts Receivable -------
Inventories -------
Accounts Payable -------
Capital Expenditure -------
UFCF -------
WACC
PV UFCF -------
SUM PV UFCF -

Terminal Value

Growth in perpetuity method:
Long-term growth rate
WACC (%) -
Free cash flow (t + 1) -
Terminal Value -
Present Value of Terminal Value -

Intrinsic Value

Enterprise Value -
Net Debt -
Equity Value -
Shares Outstanding -
Equity Value Per Share -